News | Intravascular Imaging | May 20, 2016

Optimal Imaging Matches Intravascular Ultrasound for Guiding PCI

OPINION study shows good clinical outcomes with optical frequency domain imaging

PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study

May 20, 2016 — Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation drug eluting stents (DES) achieves equivalent clinical and angiographic outcomes to intravascular ultrasound (IVUS)-guided PCI at 12 months. This conclusion was part of results of the OPINION study, reported in a late-breaker session at EuroPCR 2016.

IVUS is an imaging modality used to assess lesion morphology during PCI, and several studies have reported that IVUS guidance in PCI might be helpful to improve outcomes. OFDI is the most recently developed optical coherence tomography (OCT) technology that uses light rather than ultrasound to give high-resolution imaging.

"OPINION is the first study to compare clinical outcomes with OFDI and IVUS to assess lesion morphology during PCI with second-generation drug-eluting stents," explained study author Takashi Kubo, from Wakayama University, Wakayama, Japan.

The OPINION study researchers randomized 800 patients (mean age 68 years) scheduled for PCI using DES to either OFDI-guided PCI or IVUS-guided PCI at 42 centers in Japan. Patients underwent PCI using drug-eluting stents with resorbable polymer in de novo native coronary artery lesions. They were followed-up with angiography at eight months and the primary endpoint was target vessel failure assessing during clinical follow-up at 12 months.

Results of the non-inferiority study reported at EuroPCR 2016 showed a similarly low rate of target vessel revascularization — a composite of cardiac death, target vessel-related MI and clinically driven target vessel revascularization — at 12 months in patients undergoing OFDI-guided PCI (5.2 percent) as in those randomized to IVUS-guided PCI (4.9 percent).

"The clinical outcome in both OCT-guided PCI and IVUS-guided PCI was excellent," reported Kubo. He suggested the study results contribute to defining the clinical value of OCT guidance in PCI. "Our results might influence the next ESC guidelines, which currently give a class IIb recommendation for OCT. OCT use during PCI should have a class IIa recommendation," he said.

Commenting on the findings, Takashi Akasaka, professor of medicine at Wakayama Medical University, Wakayama, Japan, said, "There has previously been no direct comparative data for OCT/OFDI-guided PCI and IVUS-guided PCI. The OPINION study succeeded in demonstrating that OCT-guided PCI resulted in equivalent clinical and angiographic outcomes at 12 months to IVUS-guided PCI."

Akasaka considers the clinical outcome with both imaging strategies was very good, with a low rate of target vessel revascularization, "thus, the OPINION study may contribute to define the clinical value of the OCT guidance in PCI." He agreed that the findings mean that OCT/OFDI-guided PCI should be given a class IIa recommendation.

For more information: www.europcr.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init